High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation

Annals of Hematology
Kai WilleM Griesshammer

Abstract

Venous thromboembolism (VTE) is a major burden in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN). In addition to cytoreductive treatment anticoagulation is mandatory, but optimal duration of anticoagulation is a matter of debate. In our single center study, we retrospectively included 526 MPN patients. In total, 78 of 526 MPN patients (14.8%) had 99 MPN-associated VTE. Median age at first VTE was 52.5 years (range 23-81). During a study period of 3497 years, a VTE event rate of 1.7% per patient/year was detected. 38.4% (38/99) of all VTEs appeared before or at MPN diagnosis and 55.6% (55/99) occurred at "uncommon" sites like splanchnic or cerebral veins. MPN patients with VTEs were significantly more female (p = 0.028), JAK2 positive (p = 0.018), or had a polycythemia vera (p = 0.009). MPN patients without VTEs were more often CALR positive (p = 0.023). Total study period after first VTE was 336 years with 20 VTE recurrences accounting for a recurrence rate of 6% per patient/year. In 36 of 71 MPN patients with anticoagulation therapy after first VTE event (50.7%), prophylactic anticoagulation was terminated after a median time of 6 months (range 1-61); 13 of those 36 patients (36.1%) had a VTE recurrence afte...Continue Reading

References

Aug 15, 2003·The New England Journal of Medicine·Clive KearonUNKNOWN Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators
Jan 9, 2004·The New England Journal of Medicine·Raffaele LandolfiUNKNOWN European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roberto MarchioliTiziano Barbui
Jul 8, 2005·The New England Journal of Medicine·Claire N HarrisonUNKNOWN United Kingdom Medical Research Council Primary Thrombocythemia 1 Study
Apr 17, 2007·Seminars in Hematology·Mary Cushman
Dec 8, 2009·Blood·Tiziano BarbuiGiovanni Barosi
Jun 10, 2010·Internal and Emergency Medicine·Valerio De Stefano, Ida Martinelli
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
Sep 11, 2012·Best Practice & Research. Clinical Haematology·Samuel Z Goldhaber
Dec 12, 2012·The New England Journal of Medicine·Roberto MarchioliUNKNOWN CYTO-PV Collaborative Group
Jul 3, 2013·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY Investigators
Jul 17, 2013·British Journal of Haematology·Mallika SekharAndrew K Burroughs
Sep 3, 2013·The New England Journal of Medicine·Harry R BüllerPhil Wells
Feb 15, 2015·Annals of Hematology·Juan-Carlos Hernández-BoludaUNKNOWN Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Jun 3, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malin HultcrantzMagnus Björkholm
Mar 6, 2016·Journal of Hematology & Oncology·A KaifieUNKNOWN Study Alliance Leukemia (SAL)
Dec 20, 2016·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Jun 7, 2017·Annals of Hematology·Irene BertozziMaria Luigia Randi

❮ Previous
Next ❯

Citations

Mar 9, 2019·Annals of Hematology·Martin GriesshammerCarlos Besses
Nov 23, 2021·Journal of Cancer Research and Clinical Oncology·Carl C CrodelFlorian H Heidel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.